In the fourth quarter of fiscal year 2026, Sun Pharma reported a 26% year-on-year increase in profit, reaching ₹2,714 crore. The company's total revenue from operations for the quarter rose by 12.8% to ₹14,611.79 crore. Reflecting its financial health, Sun Pharma's board has recommended a final dividend of ₹5 per share for the fiscal year 2026. These results highlight the company's continued growth in the Indian pharmaceutical sector amid a competitive market environment. Sun Pharma Q4 results 2026: Profit jumped 26% YoY to ₹2,714 crore. Total revenue from operations for the quarter under review rose 12.8% YoY to ₹14,611.79 crore.